Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Magn Reson Imaging. 2011 Nov 12;30(2):261–270. doi: 10.1016/j.mri.2011.09.006

Table 1.

The pharmacological profile test results of l-THP

Receptor Percent inhibition Radioligand Kd (M)
Adrenergic, a1A 55.78 [3H]-7-meoxy-prazosin 4.0E–10
Adrenergic, a2A (h) 61.20 [3H]-MK-912 0.5E–9
DA, D1 (hr) 97.34 [3H]-SCH23390 2.0E–9
DA, D2 (hr) 87.37 [3H]-spiperone 1E–10
DA, D3 82.92 [3H]7-OH-DPAT 0.9E–9
Serotonin, 5HT1A (hr) 100.79 [3H]8-OH-DPAT 0.8E–9
Serotonin, 5HT1D 75.89 [3H]-5-CT 2.5E–9
Serotonin, 5HT4 73.60 [3H]GR 113808 0.1E–9
Serotonin, 5HT7 (hr) 76.81 [3H]-LSD 3E–9
Cannabinoid, CB1 (hr) −5.64 [3H]-CP 55940 0.6E–9
Muscarinic, M1 (hr) 4.65 [3H]scopolamine,N-methyl 5E–11
Opiod, Mu (hr) 6.96 [3H]-diprenorphine 2E–10

Receptors in bold letters indicate significantly high-binding affinity of l-THP. Percent inhibition of 50% or greater is taken as active binding. Kd values of radioligands are listed as reference in the far right column. H, human; hr, human recombinant. DPAT, Dipropylamino-tetrahydronaphthalen; CT, Carboxamidotryptamine; LSD, Lysergic acid diethylamide.